Abstract:RATIONALE AND OBJECTIVES:Glioblastoma multiforme (GBM) is the most common and deadly type of primary malignant tumor of the central nervous system. Accurate risk stratification is vital for a more personalized approach in GBM management. The purpose of this study is to develop and validate a MRI-based prognostic quantitative radiomics classifier in patients with newly diagnosed GBM and to evaluate whether the classifier allows stratification with improved accuracy over the clinical and qualitative imaging features risk models.METHODS:Clinical and MR imaging data of 127 GBM patients were obtained from the Cancer Genome Atlas and the Cancer Imaging Archive. Regions of interest corresponding to high signal intensity portions of tumor were drawn on postcontrast T1-weighted imaging (post-T1WI) on the 127 patients (allocated in a 2:1 ratio into a training [n = 85] or validation [n = 42] set), then 3824 radiomics features per patient were extracted. The dimension of these radiomics features were reduced using the minimum redundancy maximum relevance algorithm, then Cox proportional hazard regression model was used to build a radiomics classifier for predicting overall survival (OS). The value of the radiomics classifier beyond clinical (gender, age, Karnofsky performance status, radiation therapy, chemotherapy, and type of resection) and VASARI features for OS was assessed with multivariate Cox proportional hazards model. Time-dependent receiver operating characteristic curve analysis was used to assess the predictive accuracy.RESULTS:A classifier using four post-T1WI-MRI radiomics features built on the training dataset could successfully separate GBM patients into low- or high-risk group with a significantly different OS in training (HR, 6.307 [95% CI, 3.475-11.446]; p < 0.001) and validation set (HR, 3.646 [95% CI, 1.709-7.779]; p < 0.001). The area under receiver operating characteristic curve of radiomics classifier (training, 0.799; validation, 0.815 for 12-month) was higher compared to that of the clinical risk model (Karnofsky performance status, radiation therapy; training, 0.749; validation, 0.670 for 12-month), and none of the qualitative imaging features was associated with OS. The predictive accuracy was further improved when combined the radiomics classifier with clinical data (training, 0.819; validation: 0.851 for 12-month).CONCLUSION:A classifier using radiomics features allows preoperative prediction of survival and risk stratification of patients with GBM, and it shows improved performance compared to that of clinical and qualitative imaging features models.

Biological underpinnings of radiomic magnetic resonance imaging phenotypes for risk stratification in IDH wild-type glioblastoma

The Prognostic Value and Biological Significance of MRI CE-T1-based Radiomics Models in CNS5-identified GBM: a Multi-Center Study

Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma

Radiogenomics to characterize the immune-related prognostic signature associated with biological functions in glioblastoma

Radiomics-based survival risk stratification of glioblastoma is associated with different genome alteration

Magnetic Resonance Imaging and Deoxyribonucleic Acid Methylation–based Radiogenomic Models for Survival Risk Stratification of Glioblastoma

Development and Validation of a MRI-Based Radiomics Prognostic Classifier in Patients with Primary Glioblastoma Multiforme.

Biologic Pathways Underlying Prognostic Radiomics Phenotypes from Paired MRI and RNA Sequencing in Glioblastoma

Radiomic profiling for insular diffuse glioma stratification with distinct biologic pathway activities

Multiregional Radiomics Profiling from Multiparametric MRI: Identifying an Imaging Predictor of IDH1 Mutation Status in Glioblastoma

Diffusion tensor imaging‐based machine learning for <scp>IDH</scp> wild‐type glioblastoma stratification to reveal the biological underpinning of radiomic features

A radiomics-clinical nomogram for preoperative prediction of IDH1 mutation in primary glioblastoma multiforme.

Quantitative MRI-based Radiomics for Noninvasively Predicting Molecular Subtypes and Survival in Glioma Patients

Radiomics and Qualitative Features From Multiparametric MRI Predict Molecular Subtypes in Patients With Lower-Grade Glioma

Nimg-79. A Radiomic-Risk Score For Survival Prediction In Glioma: A Large Multi-Institutional Retrospective Validation Study

Integration of MRI radiomics and germline genetics to predict the IDH mutation status of gliomas

Insights from MRI Radiomics

Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI

Integrated MRI radiomics, tumor microenvironment, and clinical risk factors for improving survival prediction in patients with glioblastomas

Reproducible and Interpretable Machine Learning-Based Radiomic Analysis for Overall Survival Prediction in Glioblastoma Multiforme

Radiomic Profiles in Diffuse Glioma Reveal Distinct Subtypes with Prognostic Value